Thromboplastin Calibration and Oral Anticoagulant Control: Developments in Hematology and Immunology, cartea 8
Editat de A.M.H.P. van den Besselaar, H.R. Gralnick, S.M. Lewisen Limba Engleză Paperback – 22 dec 2011
Din seria Developments in Hematology and Immunology
- 5% Preț: 715.19 lei
- 5% Preț: 1098.84 lei
- 5% Preț: 1414.64 lei
- 5% Preț: 358.84 lei
- 5% Preț: 366.70 lei
- 5% Preț: 2115.92 lei
- 5% Preț: 723.21 lei
- 5% Preț: 388.48 lei
- 5% Preț: 361.23 lei
- 5% Preț: 361.80 lei
- 5% Preț: 1103.22 lei
- 5% Preț: 720.68 lei
- 5% Preț: 362.37 lei
- 5% Preț: 721.77 lei
- 5% Preț: 1414.29 lei
- 5% Preț: 2117.93 lei
- 5% Preț: 1418.68 lei
- 5% Preț: 1102.46 lei
- 5% Preț: 722.33 lei
- 5% Preț: 720.10 lei
- 5% Preț: 724.14 lei
- 18% Preț: 951.91 lei
- 5% Preț: 1414.64 lei
- 5% Preț: 1100.64 lei
- 5% Preț: 1100.30 lei
- 5% Preț: 1097.18 lei
- 5% Preț: 1105.77 lei
- 15% Preț: 592.59 lei
- 5% Preț: 1414.29 lei
- 5% Preț: 983.17 lei
- 5% Preț: 1105.77 lei
Preț: 367.84 lei
Preț vechi: 387.20 lei
-5% Nou
Puncte Express: 552
Preț estimativ în valută:
70.40€ • 73.30$ • 59.49£
70.40€ • 73.30$ • 59.49£
Carte tipărită la comandă
Livrare economică 07-21 martie
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9789401090056
ISBN-10: 940109005X
Pagini: 276
Ilustrații: 274 p.
Dimensiuni: 155 x 235 x 14 mm
Greutate: 0.4 kg
Ediția:Softcover reprint of the original 1st ed. 1984
Editura: SPRINGER NETHERLANDS
Colecția Springer
Seria Developments in Hematology and Immunology
Locul publicării:Dordrecht, Netherlands
ISBN-10: 940109005X
Pagini: 276
Ilustrații: 274 p.
Dimensiuni: 155 x 235 x 14 mm
Greutate: 0.4 kg
Ediția:Softcover reprint of the original 1st ed. 1984
Editura: SPRINGER NETHERLANDS
Colecția Springer
Seria Developments in Hematology and Immunology
Locul publicării:Dordrecht, Netherlands
Public țintă
ResearchCuprins
1. Introduction.- 2. General Aspects of Thromboplastin Calibration.- 3. Orthogonal Regression Equation.- 4. The European Community Bureau of Reference Calibration Study.- 5. A Statistician’s Independent Evaluation.- 6. Critical Remarks from a Clinician’s Point of View.- Discussion.- 7. The Manufacturers’ Calibration Study.- 8. INR Ranges and Targets for Oral Anticoagulation to be Effective and Safe.- Discussion.- 9. The British System of Oral Anticoagulant Control and its Relation with the W.H.O. System: Calibration of the Proposed Second W.H.O. International Reference Thromboplastin (BCT/253).- 10. Anomalies of Thromboplastin Nomenclature.- 11. Comparison of a Highly Sensitive Rabbit Brain Thromboplastin, Dade Thromboplastin FS, with a Human Brain Thromboplastin, Manchester Comparative Thromboplastin.- Comment on Dr. Spaethe’s contribution.- 12. Proficiency Testing and Standardization of Prothrombin Time — Potential Use of Thromboplastin Calibration in the United States.- 13. The Relationship between the International Normalized Ratio and the Coumarin-Induced Coagulation Defect.- Discussion.- 14. Joint ICTH/ICSH Proposed Policy Statement with Respect to Reporting the Prothrombin Time in Oral Anticoagulant Control.- Discussion.- 15. A Manufacturer’s View of Thromboplastin Calibration (I).- 16. A Manufacturer’s View of Thromboplastin Calibration (II).